207 related articles for article (PubMed ID: 34320230)
1. Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
Cao Y; Zhang W; Li Y; Fu J; Li H; Li X; Gao X; Zhang K; Liu S
Prostate; 2021 Oct; 81(14):1071-1077. PubMed ID: 34320230
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM
JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA
Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057
[TBL] [Abstract][Full Text] [Related]
4. Variations in Age-Adjusted Prostate Cancer Incidence Rates by Race and Ethnicity After Changes in Prostate-Specific Antigen Screening Recommendation.
Lai SM; Keighley J; Garimella S; Enko M; Parker WP
JAMA Netw Open; 2022 Nov; 5(11):e2240657. PubMed ID: 36342715
[TBL] [Abstract][Full Text] [Related]
5. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015.
Dall'Era MA; deVere-White R; Rodriguez D; Cress R
Eur Urol Focus; 2019 Nov; 5(6):1014-1021. PubMed ID: 29735368
[TBL] [Abstract][Full Text] [Related]
6. Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013.
Houston KA; King J; Li J; Jemal A
J Urol; 2018 Mar; 199(3):676-682. PubMed ID: 28965781
[TBL] [Abstract][Full Text] [Related]
7. Trends in Incidence of Metastatic Prostate Cancer in the US.
Desai MM; Cacciamani GE; Gill K; Zhang J; Liu L; Abreu A; Gill IS
JAMA Netw Open; 2022 Mar; 5(3):e222246. PubMed ID: 35285916
[TBL] [Abstract][Full Text] [Related]
8. Contemporary Trends in the Incidence of Metastatic Prostate Cancer Among US Men: Results from Nationwide Analyses.
Dalela D; Sun M; Diaz M; Karabon P; Seisen T; Trinh QD; Menon M; Abdollah F
Eur Urol Focus; 2019 Jan; 5(1):77-80. PubMed ID: 28753893
[TBL] [Abstract][Full Text] [Related]
9. Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004-2014.
Li J; Siegel DA; King JB
Ann Epidemiol; 2018 May; 28(5):328-330. PubMed ID: 29678312
[TBL] [Abstract][Full Text] [Related]
10. Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995-2012.
Hoffman RM; Meisner AL; Arap W; Barry M; Shah SK; Zeliadt SB; Wiggins CL
Cancer Epidemiol Biomarkers Prev; 2016 Feb; 25(2):259-63. PubMed ID: 26646364
[TBL] [Abstract][Full Text] [Related]
11. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
Negoita S; Feuer EJ; Mariotto A; Cronin KA; Petkov VI; Hussey SK; Benard V; Henley SJ; Anderson RN; Fedewa S; Sherman RL; Kohler BA; Dearmon BJ; Lake AJ; Ma J; Richardson LC; Jemal A; Penberthy L
Cancer; 2018 Jul; 124(13):2801-2814. PubMed ID: 29786851
[TBL] [Abstract][Full Text] [Related]
12. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
13. Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.
Jemal A; Culp MB; Ma J; Islami F; Fedewa SA
J Natl Cancer Inst; 2021 Jan; 113(1):64-71. PubMed ID: 32432713
[TBL] [Abstract][Full Text] [Related]
14. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
[TBL] [Abstract][Full Text] [Related]
15. Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation.
Kensler KH; Pernar CH; Mahal BA; Nguyen PL; Trinh QD; Kibel AS; Rebbeck TR
J Natl Cancer Inst; 2021 Jun; 113(6):719-726. PubMed ID: 33146392
[TBL] [Abstract][Full Text] [Related]
16. Trends for Stage and Grade Group of Prostate Cancer in the US (2010-2016).
Schmanke K; Okut H; Ablah E
Urology; 2021 Mar; 149():110-116. PubMed ID: 33227304
[TBL] [Abstract][Full Text] [Related]
17. An Up-to-date Assessment of US Prostate Cancer Incidence Rates by Stage and Race: A Novel Approach Combining Multiple Imputation with Age and Delay Adjustment.
Cook MB; Hurwitz LM; Geczik AM; Butler EN
Eur Urol; 2021 Jan; 79(1):33-41. PubMed ID: 33092896
[TBL] [Abstract][Full Text] [Related]
18. Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score.
Herget KA; Patel DP; Hanson HA; Sweeney C; Lowrance WT
Cancer Med; 2016 Jan; 5(1):136-41. PubMed ID: 26628287
[TBL] [Abstract][Full Text] [Related]
19. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
[TBL] [Abstract][Full Text] [Related]
20. PSA screening and deaths from prostate cancer after diagnosis--a population based analysis.
Wachtel MS; Nelius T; Haynes AL; Dahlbeck S; de Riese W
Prostate; 2013 Sep; 73(12):1365-9. PubMed ID: 23649537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
